Cargando…

Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma

BACKGROUND: T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somatic mutations. However, few neoantigens per patient could i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Qin, Zhang, Chaoting, Yang, Wenjun, Liu, Ying, Heyilimu, Palashati, Feng, Dongdong, Xing, Liying, Ke, Yang, Lu, Zheming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714102/
https://www.ncbi.nlm.nih.gov/pubmed/31462302
http://dx.doi.org/10.1186/s40425-019-0709-7
_version_ 1783446989623525376
author Tan, Qin
Zhang, Chaoting
Yang, Wenjun
Liu, Ying
Heyilimu, Palashati
Feng, Dongdong
Xing, Liying
Ke, Yang
Lu, Zheming
author_facet Tan, Qin
Zhang, Chaoting
Yang, Wenjun
Liu, Ying
Heyilimu, Palashati
Feng, Dongdong
Xing, Liying
Ke, Yang
Lu, Zheming
author_sort Tan, Qin
collection PubMed
description BACKGROUND: T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somatic mutations. However, few neoantigens per patient could induce immune response in epithelial cancer and additionally many tumor-specific antigens could be derived from noncoding region. Autologous tumor cells (ATCs) could be unbiased stimulators in activating and enriching tumor-reactive T cells. However, it’s unknown if T cells engineered to express TCRs isolated from tumor-reactive T cells enriched by ATCs have strong antitumor response. METHODS: In this study, multiple TIL fragments obtained from a patient with esophageal squamous cell carcinoma (ESCC) were screened for specific recognition of ATCs. Tumor-reactive TILs were enriched by in vitro repeated stimulation of ATCs and isolated based on CD137 upregulation. Subsequently, tumor-reactive TCR was obtained by single-cell RT-PCR analysis and was introduced into peripheral blood lymphocytes to generate TCR-Ts. RESULTS: We found that phenotype and effect function of TIL fragments derived from different tumor sites were spatially heterogeneous. Of four TIL fragments, only TIL-F1 could specifically identify ATCs. Subsequently, we isolated CD8(+) CD137(+) T cells from pre- and post-stimulated TIL-F1 co-cultured with ATCs, and identified their most dominant TCR. This TCR was introduced into PBLs to generate TCR-Ts, which specifically identified and killed ATCs in vivo and in vitro. CONCLUSION: This strategy provides the means to generate tumor-reactive TCR-Ts for ESCC, which is especially important for patients without prior knowledge of specific epitopes and might be applied for other cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0709-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6714102
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67141022019-09-04 Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma Tan, Qin Zhang, Chaoting Yang, Wenjun Liu, Ying Heyilimu, Palashati Feng, Dongdong Xing, Liying Ke, Yang Lu, Zheming J Immunother Cancer Research Article BACKGROUND: T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somatic mutations. However, few neoantigens per patient could induce immune response in epithelial cancer and additionally many tumor-specific antigens could be derived from noncoding region. Autologous tumor cells (ATCs) could be unbiased stimulators in activating and enriching tumor-reactive T cells. However, it’s unknown if T cells engineered to express TCRs isolated from tumor-reactive T cells enriched by ATCs have strong antitumor response. METHODS: In this study, multiple TIL fragments obtained from a patient with esophageal squamous cell carcinoma (ESCC) were screened for specific recognition of ATCs. Tumor-reactive TILs were enriched by in vitro repeated stimulation of ATCs and isolated based on CD137 upregulation. Subsequently, tumor-reactive TCR was obtained by single-cell RT-PCR analysis and was introduced into peripheral blood lymphocytes to generate TCR-Ts. RESULTS: We found that phenotype and effect function of TIL fragments derived from different tumor sites were spatially heterogeneous. Of four TIL fragments, only TIL-F1 could specifically identify ATCs. Subsequently, we isolated CD8(+) CD137(+) T cells from pre- and post-stimulated TIL-F1 co-cultured with ATCs, and identified their most dominant TCR. This TCR was introduced into PBLs to generate TCR-Ts, which specifically identified and killed ATCs in vivo and in vitro. CONCLUSION: This strategy provides the means to generate tumor-reactive TCR-Ts for ESCC, which is especially important for patients without prior knowledge of specific epitopes and might be applied for other cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0709-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-28 /pmc/articles/PMC6714102/ /pubmed/31462302 http://dx.doi.org/10.1186/s40425-019-0709-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tan, Qin
Zhang, Chaoting
Yang, Wenjun
Liu, Ying
Heyilimu, Palashati
Feng, Dongdong
Xing, Liying
Ke, Yang
Lu, Zheming
Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
title Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
title_full Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
title_fullStr Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
title_full_unstemmed Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
title_short Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
title_sort isolation of t cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of t cell receptor engineered t cells for esophageal squamous cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714102/
https://www.ncbi.nlm.nih.gov/pubmed/31462302
http://dx.doi.org/10.1186/s40425-019-0709-7
work_keys_str_mv AT tanqin isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma
AT zhangchaoting isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma
AT yangwenjun isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma
AT liuying isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma
AT heyilimupalashati isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma
AT fengdongdong isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma
AT xingliying isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma
AT keyang isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma
AT luzheming isolationoftcellreceptorspecificallyreactivewithautologoustumourcellsfromtumourinfiltratinglymphocytesandconstructionoftcellreceptorengineeredtcellsforesophagealsquamouscellcarcinoma